Grant Yonehiro

Grant Yonehiro joined Bolt Biotherapeutics as the company’s chief business officer in 2016. Grant has been responsible for business and corporate development, strategy, commercialization and general management within biotechnology companies for over 25 years with significant transactional and operational responsibilities. He served as president and chief executive officer of Perseid Therapeutics from inception through acquisition by Astellas Pharma and stayed on post-acquisition as president of an Astellas operating site. He served as chief business officer for Berkeley Lights and Maxygen and also held various senior management positions at GenVec including vice president of commercial operations, vice president of product management and vice president of drug development. Prior to GenVec, he served in business development at Cell Genesys, in investment banking at Piper Jaffray and in the Technology Transfer Office at Lawrence Berkeley National Laboratory. Grant graduated Magna Cum Laude from the University of Minnesota with a Bachelor of Individualized Studies and received his M.B.A. from the Haas School of Business at UC Berkeley.